Evidence map›Paper›PMID 26679888›Full record

ArticleSpine2016

Binding to COMP Reduces the BMP2 Dose for Spinal Fusion in a Rat Model.

Motasem Refaat, Eric O Klineberg, Michael C Fong, Tanya C Garcia, J Kent Leach, Dominik R Haudenschild

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Spine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Motasem RefaatLawrence J. Ellison Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of California Davis, Davis, CA.
Eric O KlinebergLawrence J. Ellison Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of California Davis, Davis, CA.
Michael C FongLawrence J. Ellison Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of California Davis, Davis, CA.
Tanya C GarciaJ.D. Wheat Veterinary Orthopaedic Laboratory, School of Veterinary Medicine, University of California Davis, One Shields Avenue, Davis, CA.
J Kent LeachLawrence J. Ellison Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of California Davis, Davis, CA.
Dominik R HaudenschildLawrence J. Ellison Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of California Davis, Davis, CA.
University of California, Davis · USUniversity of California Davis Medical Center · US

Funding

UC Davis Clinical and Translational Science CenterUL1TR000002 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$12.2M
NCATS NIH HHS UL1 TR000002
6 · The paper itself

Abstract

STUDY

designThe aim of this study is to test the effect of cartilage oligomeric matrix protein (COMP) on enhancing rhBMP-2 induced spinal fusion in a prospective 8-week interventional trial of spinal fusion in rats.

objectiveTo determine whether the amount of bone morphogenetic protein-2 (BMP-2) required to achieve spinal fusion in a pre-clinical model can be reduced by the addition of COMP. SUMMARY OF BACKGROUND DATA: BMPs are applied clinically at supraphysiological doses to promote spinal fusion by inducing osseous growth, but dose-related limitations include ectopic bone formation and local inflammatory reactions. COMP is a matricellular BMP-binding protein expressed during endochondral ossification and fracture healing. In vitro studies demonstrate enhanced activity of BMP bound to COMP. We hypothesized that BMP bound to COMP could achieve equivalent spinal fusion rates at lower doses and with fewer complications.

methodsPosterolateral intertransverse process spinal fusion at L4 to L5 was performed in 36 Lewis rats. COMP (10 μg) was tested with or without "low-dose" rhBMP-2 (2 μg), and the results were compared with the "low-dose" (2 μg rhBMP-2) and "high-dose" (10 μg rhBMP-2) groups. All groups utilized insoluble collagen bone matrix carrier (ICBM). Fusion was evaluated by radiology, histology, and manual palpation. BMP release kinetics were evaluated in vitro.

resultsFusion grading of microCT images demonstrated that the fusion rate with the COMP+LoBMP was statistically equivalent to HiBMP, and significantly better than LoBMP without COMP. These results were confirmed with radiographs and manual palpation. BMP release kinetics suggest that COMP increased local concentrations of BMP due to decreased growth factor retention on the scaffold.

conclusionCOMP enhances BMP-induced bone formation, enabling lower doses of BMP to achieve the same level of spinal fusion. COMP may function by affecting the availability and biological presentation of BMP-2. A decrease of BMP-2 required for fusion may reduce dose-related adverse effects, surgical costs, and improve clinical outcomes. LEVEL OF EVIDENCE: N/A.

Indexed as

Spinal FusionAnimalsBone MatrixBone Morphogenetic Protein 2Cartilage Oligomeric Matrix ProteinDisease Models, AnimalHumansLumbar VertebraeMaleRats, Inbred LewRecombinant ProteinsBMP2 protein, humanBone Morphogenetic Protein 2Cartilage Oligomeric Matrix ProteinRecombinant Proteins

Identifiers

PMID26679888
PMCPMC7054986
OpenAlexW2328096047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.